Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas

Cancer Research

Volumn 63, Issue 2, 2003, Pages 441-448

  Takeuchi, Hiroya ^a   Kuo, Christine ^a   Morton, Donald L ^b   Wang, He Jing ^a   Hoon, Dave S B ^a,b  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MELANOMA ANTIGEN; MELANOMA ASSOCIATED ANTIGEN; MESSENGER RNA; PROTEIN MART1; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TIME SERIES ANALYSIS; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANTIGENS, NEOPLASM; GENE EXPRESSION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0037439963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rigel, D. S., Frieman, R. J., and Kopf, A. W. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol., 34: 839-847, 1996.
2. Jemal, A. J., Thomas, A., Murray, T., and Thun, M. Cancer Statistics. 2002. CA Cancer J. Clin., 52: 23-47, 2002.
3. Balch, C. M., Buzaid, A. C., Soong, S-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A. Jr., Kirkwood, J. M., McMasters, K. M., Mihm, M. F., Morton, D. L., Reintgen, D. S., Ross, M. I., Sober, A., Thompson, J. A., and Thompson, J. F. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J. Clin. Oncol., 16: 3635-3648, 2001.
4. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., and Irie, R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216: 463-482, 1992.
5. Morton, D. L., and Barth, A. Vaccine therapy for malignant melanoma. CA. Cancer J. Clin., 46: 225-244, 1996.
6. Jager, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jager, D., Ilsemann, C., Hagedorn, M., Oesch, F., and Knuth, A. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer, 67: 54-62, 1996.
7. Hsueh, E. C., Nathanson, L., Foshag, L. J., Essner, R., Nizze, J. A., Stem, S. L., and Morton, D. L. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer (Phila.), 85: 2160-2169, 1999.
8. Scheibenbogen, C., Nagorsen, D., Seliger, B., Schmittel, A., Letsch, A., Bauer, S., Max, N., Bock, M., Atkins, D., Thiel, E., and Keilholz, U. Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int. J. Cancer, 99: 403-408, 2002.
9. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.
10. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
11. Wang, R. F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med., 184: 2207-2216, 1996.
12. Mitchell, M. S., Darrah, D., Yeung, D., Halpem, S., Wallace, A., Voland, J., Jones, V., and Kan-Mitchell, J. Phase I trial of adoptive immunotherapy with cytotoxic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol., 20: 1075-1086, 2002.
13. Rivoltini, L., Loftus, D. J., Squarcina, P., Castelli, C., Rini, F., Arienti, F., Belli, F., Marincola, F. M., Geisler, C., Borsatti, A., Appella, E., and Parmiani, G. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumor T-cell reactivity. Crit. Rev. Immunol., 18: 55-63, 1998.
14. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E., and Celis, E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res., 61: 4773-4778, 2001.
15. Huang, S. K., Okamoto, T., Morton, D. L., and Hoon, D. S. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Investig. Dermatol., 111: 662-667, 1998.
16. Okamoto, T., Irie, R. F., Fujii, S., Huang, S. K., Nizze, A. J., Morton, D. L., and Hoon, D. S. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J. Investig. Dermatol., 111: 1034-1039, 1998.
17. Fujii, S., Huang, S., Fong, T. C., Ando, D., Burrows, F., Jolly, D. J., Nemunaitis, J., and Hoon, D. S. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther. 7: 1220-1230, 2000.
18. Hoon, D. S., Yuzuki, D., Hayashida, M., and Morton, D. L. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J. Immunol., 154: 730-737, 1995.
19. Celis, E., Fikes, J., Wentworth, P., Sidney, J., Southwood, S., Maewal, A., Del Guercio, M. F., Sette, A., and Livingston, B. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol., 31: 1423-1430, 1994.
20. Marincola, F. M., Jaffee, E. M., Hickun, D. J., and Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74: 181-273, 2000.
21. Hoon. D. S. B., Bostick, P., Kuo, C., Okamoto, T., Wang H-J., Elashoff, R., and Morton, D. L. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res., 60: 2253-2257, 2000.
22. Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A. J., Schmid, P. Morton, D. L., and Hoon, D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
23. Bostick, P. J., Morton, D. L., Turner, R. R., Huynh, K. T., Wang, H-J., Elashoff, R., Essner, R., and Hoon, D. S. B. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol., 17: 3238-3244, 1999.
24. Miyashiro, I., Kuo, C., Huynh, K., Iida, A., Morton, D., Bilchik, A., Giuliano, A., and Hoon, D. S. B. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin. Chem., 47: 505-512, 2001.
25. Morton, D. L., Ollila, D. W., Hsueh, E. C., Essner, R., and Gupta, R. K. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA. Cancer J. Clin., 49: 101-116, 1999.
26. Seliger, B., Maeurer, M. J., and Ferrone, S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21: 455-464, 2000.
27. Wood, T. F., DiFronzo, L. A., Rose, D. M., Haigh, P. I., Stem, S. L., Wanek, L., Essner, R., and Morton, D. L. Does complete resection of melanoma metastatic to solid intraabdominal organs improve survival? Ann. Surg. Oncol., 8: 658-662, 2001.
28. Wider, A., Kobayashi, T., Katschiko, T., Urabe, K., Aroca, P., Kameyama, K., and Hearing, V. J. The tyrosinase gene family-interactions of melanogenic proteins to regulate melanogenesis. Cell. Mol. Biol. Res., 40: 613-626, 1994.
29. Jimenez-Cervantes, C., Solano, F., Kobayashi, T., Urabe, K., Hearing, V. J., Lozano, J. A., and Garcia-Borron, J. C. A new enzymatic function in the melanogenic pathway. J. Biol. Chem., 269: 17993-18001, 1994.
30. Andersen, M. H., Keikavoussi, P., Brocker, E. B., Schuler-Thumer, B., Jonassen, M., Sondergaard, I., Straten, P. T., Becker, J. C., and Kampgen, E. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int. J. Cancer, 94: 820-824, 2001.
31. Chang, A. E., Redman, B. G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. P., Geiger, J. D., and Mule, J. J. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res., 8: 1021-1032, 2002.
32. Clegg, R. M. Fluorescence energy transfer. Curr. Opin. Biotech., 6: 103-110, 1995.
33. Bilchik, A. J., Saha, S., Wiese, D., Stonecypher, J. A., Wood, T. F., Sostrin, S., Turner, R. R., Wang, H-J., Morton, D. L., and Hoon, D. S. B. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J. Clin. Oncol., 19: 1128-1136, 2001.
34. Kielar, D., Dietmaier, W., Langmann, T., Aslanidis, C., Probst, M., Naruszewicz, M., and Schmitz, G. Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem., 47: 2089-2097, 2001.
35. Suzuki, R., Takemura, K., Tsutsumi, M., Nakamura, S., Hamajima, N., and Seto, M. Detection of cyclin D1 overexpression by real-time reverse-transcriptase-mediated quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma. Am. J. Pathol., 159: 425-429, 2001.
36. Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., and Ferrone, S. β2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. lnvestig., 101: 2720-2729, 1998.
37. Chi, D. D., Merchant, R. E., Rand, R., Conrad, A. J., Garrison, D., Turner, R., Morton, D. L., and Hoon, D. S. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J. Pathol., 150: 2143-2152, 1997.
38. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. J. Natl. Cancer Inst. (Bethesda), 78: 45-54, 1987.
39. Spruck, C. H., III, Gonzalez-Zulueta, M., and Shibata, A. p16 gene in uncultured tumors. Nature (Lond.), 370: 183-184, 1994.
40. Cormier, J. N., Panelli, M. C., Hackett, J. A., Bettinotti, M., Mixon, A., Wunderlich, J., Parker, L., Restifo, N. P., Ferrone, S., and Marincola, F. M. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer, 80: 781-790, 1999.
41. Morton, D. L., Thompson, J. F., Essner, R., Elashoff, R., Stern, S. L., Nieweg, O. E., Roses, D. F., Karakousis, C. P., Mozzillo, N., Reintgen, D., Wang, H. J., Glass, E. C., and Cochran, A. J. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter selective lymphadenectomy trial group. Ann. Surg., 230: 453-463, 1999.
42. Ricker, A. I., Kammula, U. S., Panelli, M. C., Wang, E., Ohnmacht, G. A., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int. J. Cancer, 86: 818-826, 2000.
43. Brouwenstijn, N., Slager, E. H., Bakker, A. B., Schreurs, M. W., Van der Spek, C. W., Adema, G. W., Schrier, P. I., and Figdor, C. G. Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br. J. Cancer, 76: 1562-1566, 1997.
44. de Vries, T. J., Smeets, M., de Graaf, R., Hou-Jensen, K., Brocker, E., B., Renard, N., Eggermont, A. M., van Muijen, G. N., and Ruiter, D. J. Expression of gp100 MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conduced by the EORTC Melanoma Cooperative Group. J. Pathol., 193: 13-20, 2001.
45. Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Investig., 98: 1633-1641, 1996.